Diagnostic Substances
(ABAX) Abaxis Analyst Upgrades Shares to Neutral
Following the company’s solid second quarter 2011 results, which were ahead of the Zacks Consensus Estimates, we have upgraded our recommendation on Abaxis (ABAX) to Neutral with a target price of $26.00. The company reported EPS of 15 cents in the quarter, surpassing the Zacks...
1Dec2011 | vitalstocks | 0 comments | Continued(ABAX) Alere Takes Over Arriva Medical
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has taken over Arriva Medical, a prominent vendor of diabetes testing supplies for patients residing at home. Florida-based Arriva had sales of about...
1Dec2011 | vitalstocks | 0 comments | Continued(SRDX) SurModics Analysts Cut Shares to Neutral
We are downgrading SurModics (SRDX) to Neutral from Outperform following its setback, when partner Johnson & Johnson (JNJ) announced in June 2011 that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year-end. SurModics receives...
10Jul2011 | vitalstocks | 0 comments | Continued(BLUD) Company News for July 6, 2011 – Corporate Summary
• Share prices of Southern Union Co. (NYSE:SUG) rose 4.21% to close at $42.07 after Energy Transfer Equity, L.P. (NYSE:ETE) increased its bidding amount by 21% to $5 billion for the company, beating William’s (NYSE:WMB) bid of $4.9 billion • U.S. mining...
6Jul2011 | vitalstocks | 0 comments | Continued(BLUD) Immucor Purchased by TPG Capital for $1.9B
Manufacturer and seller of automated systems and reagents, Immucor Inc. (BLUD) recently announced that it will be taken over by private equity group TPG Capital for $1.97 billion. As per the terms of the agreement, Immucor’s shareholders will receive $27 in cash for each share...
6Jul2011 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform
Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion...
1Jul2011 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Bull of the Day
Myriad Genetics’ (MYGN) flagship product, Bracanalysis, has been recording robust growth over the past few quarters. Moreover, the company is undertaking strategies to expand the scope of the test. A strong cash balance enables the company to buyback shares, expand into...
1Jul2011 | vitalstocks | 0 comments | Continued(DDD) 3D Printing Comes of Age
by Ryan Cole, Investment U Research Analyst Monday, June 27, 2011 Yet again science fiction is becoming science fact. This time, it’s the Star Trek replicator. Granted – we don’t have the technology to rearrange molecules as we wish yet, as they do on the USS Enterprise....
27Jun2011 | InvestmentU | 0 comments | Continued(AMAG) AMAG Pharmaceuticals Gets Label Update for Feraheme
AMAG Pharmaceuticals Inc. (AMAG) recently announced a label update for its lead drug Feraheme. Feraheme is an injectable drug for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients suffering from chronic kidney disease...
26Jun2011 | vitalstocks | 0 comments | Continued(SRDX) SurModics Incorporated – Bull of the Day
In June 2011, SurModics, Inc. (SRDX) received a blow when Johnson & Johnson announced that it will stop manufacturing Cypher stents by year end, as SurModics receives royalties on sales of the product. However, we believe the impact of the blow will not be very severe, and...
21Jun2011 | vitalstocks | 0 comments | Continued(AKRX) Company News for June 07, 2011 – Corporate Summary
• Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011 • According to Canaccord Genuity, data from a trial of Exelixis, Inc’s (NASDAQ:EXEL) cancer-drug candidate could...
7Jun2011 | vitalstocks | 0 comments | Continued(VIVO) FDA OKs Meridian C. Difficile Test
Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH. The approval of this next-generation test broadens the Cincinnati-based...
13May2011 | vitalstocks | 0 comments | Continued(ABAX) Alere Quarterly Earnings Beats Estimates
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, reported first-quarter fiscal 2011 adjusted earnings per share of 61 cents, beating the corresponding Zacks Consensus Estimate of 57 cents while trailing the year-ago earnings...
4May2011 | vitalstocks | 0 comments | Continued(SRDX) SurModics Analyst Increases Shares to Outperform
We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Our target price on the stock is $18.00. The company delivered strong results in the second quarter of fiscal 2011 outshining the Zacks Consensus...
4May2011 | vitalstocks | 0 comments | Continued(SRDX) SurModics Incorporated – Bull of the Day
We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Adjusted earnings in the quarter came in at $0.08 per share, well ahead of break-even earnings suggested by the Zacks Consensus Estimate. Following...
4May2011 | vitalstocks | 0 comments | Continued(PBIO) Pressure BioSciences and KeraFAST Sign Worldwide E-Commerce Distribution Deal
Grant Zeng, CFA PBIO and KeraFAST Sign Worldwide E-Commerce Distribution Deal On May 3, 2011, Pressure BioSciences, Inc. (PBIO) and KeraFAST LLC announced that they have entered into a non-exclusive, worldwide distribution agreement covering several of PBIO’s new sample preparation...
3May2011 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing
Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of...
9Apr2011 | vitalstocks | 0 comments | Continued(TRIB) Trinity Biotech – Bull of the Day
Since its Q2 2010 clinical lab coag divestiture, Trinity Biotech (TRIB) has slashed operating costs and begun pumping its huge and growing cash balance into higher growth segments. Expectations are high for the PDX instrument, expected to launch in Europe and the U.S. in 2011. Development...
17Mar2011 | vitalstocks | 0 comments | Continued(TRIB) Trinity Biotech – Bull of the Day
Since its Q2 2010 clinical lab coag divestiture, Trinity Biotech (TRIB) has slashed operating costs and begun pumping its huge and growing cash balance into higher growth segments. Expectations are high for the PDX instrument, expected to launch in Europe and the U.S. in 2011. Development...
13Mar2011 | vitalstocks | 0 comments | Continued(SRDX) SurModics Analyst Maintains Neutral Rating on Shares
SurModics (SRDX), headquartered in Eden Prairie, Minnesota, is a provider of surface modification and drug delivery technologies to the healthcare industry. Following the changes in operational structure affected in 2008, the company currently operates through the following business...
14Sep2010 | vitalstocks | 0 comments | Continued(SRDX) SurModics Signs Deal With Australian company Clinuvel Pharmaceuticals
Recently, SurModics Inc. (SRDX) inked a licensing deal with Australian company Clinuvel Pharmaceuticals Limited. The deal allows SurModics’ pharmaceuticals unit, which provides proprietary polymer-based drug delivery technologies to companies developing advanced pharmaceutical...
11Jul2010 | vitalstocks | 0 comments | Continued(PBIO) Pressure Biosciences’ Technology on Display at Harvard Medical School Symposium
Harvard Medical School Symposium On Friday, May 21, 2010, Harvard Medical School will host a symposium on the applications of ultra-high pressure in biotechnology. The full-day program focusing on the use of cycled ultra-high pressure (pressure cycling technology, or “PCT”)...
24May2010 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Bear of the Day
Myriad Genetics Inc.’s (MYGN) third quarter fiscal 2010 earnings of $0.33 per share fell short of the Zacks Consensus Estimate by $0.05. The company had earned $0.38 per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus...
23May2010 | vitalstocks | 0 comments | Continued(AMAG) AMAG Pharmaceuticals Signs Deal With Japan-Based Takeda Pharmaceutical Company
Recently, AMAG Pharmaceuticals Inc. (AMAG) and Japan-based Takeda Pharmaceutical Co. Ltd. entered into a license, development and commercialization deal related to AMAG’s Feraheme (ferumoxytol) injection for intravenous (IV) use across all potential indications for the drug. Feraheme...
6Apr2010 | vitalstocks | 0 comments | Continued(ABAX) Abaxis Analyst Maintains Neutral Rating
We recently reiterated our ‘Neutral’ rating on Abaxis, Inc. (ABAX) with a target price of $28, based on a P/E of 34.1x our fiscal 2011 EPS estimate of 82 cents. Abaxis’ results for the third quarter fiscal 2010 were mixed. Earnings per share for the third quarter was 15...
1Apr2010 | vitalstocks | 0 comments | Continued(BLUD) Immucor Third Quarter Earnings Meets Consensus Estimates
Immucor Inc. (BLUD) announced third quarter 2010 (ending in Feb 2010) earnings per share (EPS) of 28 cents, in line with the Zacks Consensus Estimate and a penny higher than the year ago quarter. Net income for the quarter was $20.1 million, compared with $19.5 million for the...
1Apr2010 | vitalstocks | 0 comments | Continued(NEOG) Neogen’s Earnings Inches Past Estimates
Neogen Corp. (NEOG) posted fiscal 2010 third-quarter results on Monday. The company’s net income recorded a strong growth of 37.5% to $3.9 million, or 17 cents per share from $2.8 million, or 12 cents per share in the year-ago period. The result also squeezed past the Zacks...
31Mar2010 | vitalstocks | 0 comments | Continued(BLUD) Immucor Third Quarter 2010 Earnings Preview
Immucor (BLUD) is scheduled to report its third quarter fiscal 2010 results on March 31, 2010. The Zacks Consensus Estimate for the quarter is pegged at a profit of 28 cents. Going by past trends, Immucor has surpassed expectations in the past four quarters. The company had a...
29Mar2010 | vitalstocks | 0 comments | Continued(SRDX) SurModics Analysts Upgrades the Stock to Neutral
We have recently upgraded our recommendation on SurModics (SRDX) to Neutral. During the first quarter of 2010, the company’s earnings per share (EPS) came in at 24 cents, surpassing the Zacks Consensus Estimate by 5 cents. Although revenues of $21 million were down 26% from...
27Mar2010 | vitalstocks | 0 comments | Continued(VIVO) Meridian Bioscience Slashes Outlook For 2010
Life science company, Meridian Bioscience, Inc. (VIVO), recently slashed its outlook for fiscal 2010 (ending Sep 30, 2010) mainly due to a weaker-than-expected H1N1 season and lower C. difficile product revenues. The company now expects net sales in the range of $145 million...
19Mar2010 | vitalstocks | 0 comments | Continued